Such factors include liver metastasis16, PS16, duration of ADT treatment16, time from prostate cancer diagnosis17, presence of pain17, PSA18,19, LDH16,17, Alb16, ALP17, Hb18, cycles of chemotherapy18, response to prior chemotherapy18, PSA decline after CRPC treatment20,21, age19, GS19, nadir PSA22, and time to nadir PSA (TNPSA)22. The gene discussed is KLK3; the disease is prostate carcinoma.